QuiaPEG

Technology

 
PEGylation
Limitations on today's technology
QuiaPEG's advantages
R&D

Research & Development 

The Company is initially developing novel long-acting biopharmaceuticals for the treatment of metabolic disorders using the Company´s proprietary technology platform. The Company´s lead project is intended to reduce the burden of frequent injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes.
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message